Why this analyst is ‘extremely bullish’ on biopharma July 30, 2024 by Alice Kennon with no comment Uncategorized Previous Post Goldman Pro Forms Invidia Capital to Invest in Healthcare Sector Next Post Exclusive: Invidia’s Jo Natauri talks new hires and decision to start her own firm
